忍者ブログ

ニュースリリースのリリースコンテナ第一倉庫

ニュースサイトなど宛てに広く配信された、ニュースリリース(プレスリリース)、 開示情報、IPO企業情報の備忘録。 大手サイトが順次削除するリリースバックナンバーも、蓄積・無料公開していきます。 ※リリース文中の固有名詞は、発表社等の商標、登録商標です。 ※リリース文はニュースサイト等マスコミ向けに広く公開されたものですが、著作権は発表社に帰属しています。

2025'07.19.Sat
×

[PR]上記の広告は3ヶ月以上新規記事投稿のないブログに表示されています。新しい記事を書く事で広告が消えます。

2007'02.01.Thu
TAXUS(R) Express (2TM) Coronary Stent System Cited by EuroIntervention for Superiority in Diabetic Patients
May 17, 2006

-- TAXUS Benefits Demonstrated in Non-Diabetic Patient Population CarryOver into Insulin-Treated Diabetic Patients
    NATICK, Mass. and PARIS, May 17 /Xinhua-PRNewswire/ --
EuroIntervention, the peer-reviewed medical journal
affiliated with the Paris Course on Revascularization,
today released an integrated analysis that further supports
the strong performance of the TAXUS(R) Express (2TM)
paclitaxel-eluting coronary stent system for the treatment
of coronary artery disease in diabetic patients.  In the
analysis, diabetic patients who received a TAXUS stent
system had significantly lower rates of restenosis and
repeat interventions than those who received a bare-metal
stent.  They study appears in the May edition of
EuroIntervention, which is the official scientific journal
of the annual Paris Course on Revascularization.

    The authors stated in the article that "The TAXUS
benefit provided for the high-risk diabetic population is
in contrast to outcomes with bare-metal stents, which are
worse for diabetic patients.  The contrast between
pro-stenotic forces with bare-metal stents and
anti-restenotic effects for diabetes receiving TAXUS
suggests that paclitaxel may also block restenotic pathways
unique to the diabetic milieu. For diabetic patients,
especially the high-risk insulin-treated group, this could
dramatically improve clinical and angiographic outcomes and
offer a less-invasive approach to a population with impaired
wound healing."

    According to the authors, a number of mechanistic
factors may contribute to the observed TAXUS benefit.  They
state that the unique mechanism of action of Paclitaxel, the
drug used in TAXUS stents, supports their conclusion of
emerging evidence of the excellent efficiency of TAXUS in
insulin-dependent diabetics.

    "We are pleased to see that, in this analysis, the
well-established benefit of TAXUS in non-diabetic patients
is carried over into the diabetic population, including the
high-risk insulin-treated subset," said Jeff Goodman,
Senior Vice President and President of International of
Boston Scientific. "Diabetics account for almost
one-quarter of patients undergoing treatment for coronary
artery disease, so these findings are very
encouraging."

    The study is the first to use an integrated analysis of
randomised data to examine aggregate results in a lower
frequency but higher-risk diabetic population. Four TAXUS
clinical trials (TAXUS II, TAXUS IV, TAXUS V and TAXUS VI)
were included in the analysis, involving a total of 3,445
patients with coronary artery stenosis, 814 of whom had
diabetes. Assessments of lesion characteristics showed that
diabetic patients on average had more complex lesions than
did non-diabetic patients. While diabetes has been
identified as a strong predictor of restenosis after
implantation of bare-metal stents, the angiographic and
clinical results of this integrated analysis with similar
outcomes independent of diabetic status suggest a
significant advantage of the TAXUS stent system in diabetic
patients, including the high risk insulin-treated subset.

    The pooled clinical trial results at nine months
reported a target lesion revascularization (TLR) rate of
5.4 in non-diabetic patients in the TAXUS group and a TLR
rate of 5.8 per cent in diabetic patients (insulin-treated)
in the TAXUS group.

    Boston Scientific is a worldwide developer,
manufacturer and marketer of medical devices whose products
are used in a broad range of interventional medical
specialties. For more information, please visit: 
http://www.bostonscientific.com .

    This press release contains forward-looking statements.
The Company wishes to caution the reader of this press
release that actual results may differ from those discussed
in the forward-looking statements and may be adversely
affected by, among other things, risks associated with
clinical trials, the regulatory approval process,
reimbursement policies, commercialisation of new
technologies, litigation, the Company's overall business
strategy and other factors described in the Company's
filings with the Securities and Exchange Commission.

    For more information, please contact:

     Geraldine Varoqui
     Boston Scientific PR Manager International
     Tel:   +49-2102-489-461
     Email: varoquig@bsci.com

     Maren Koban
     BSC press office
     Tel:   +44-207-973-4497
     Email: mkoban@hillandknowlton.com

SOURCE  Boston Scientific Corporation

PR
Post your Comment
Name:
Title:
Mail:
URL:
Color:
Comment:
pass: emoji:Vodafone絵文字 i-mode絵文字 Ezweb絵文字
trackback
この記事のトラックバックURL:
[6755] [6754] [6753] [6752] [6751] [6750] [6749] [6748] [6747] [6746] [6745
«  BackHOME : Next »
広告
ブログ内検索
カウンター

忍者ブログ[PR]